Pharmabiz

ViiV Healthcare presents data for two investigational HIV treatment therapies with potential for twice-yearly dosing

ViiV Healthcare presents data for two investigational HIV treatment therapies with potential for twice-yearly dosing: London Saturday, February 28, 2026, 13:00 Hrs [IST] ViiV Heal ...
Irish Farmers Journal

Benefits of bluetongue vaccination far outweigh the risks, vet says

The benefits of vaccinating against bluetongue far outweigh the risks of leaving animals unprotected, Jarlath Sutton of Sliabh Luachra Veterinary Centre in Rathmore, Co Kerry, has said. Veterinary ...

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, ...

Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight

Recently published Acromegaly Market Insights report includes a comprehensive understanding of current treatment practices, acromegaly emerging drugs, market share of individual therapies, and current ...

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 ...

DelveInsight Business Research, LLP: Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight

The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 ...
pharmaphorum

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
CURE

Subcutaneous Rybrevant Elicits Responses in Head and Neck Cancer Trial

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
pharmaphorum

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...
Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

Innocan Pharma Corporation: FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time

HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer ...
Precision Medicine Online

European Commission Approves Monthly Dosing for Subcutaneous Rybrevant in EGFR-Mutant NSCLC

NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...